SLONIN JONATHAN 4

What Happened
Jonathan Slonin, Chief Medical Officer of Pacira BioSciences (PCRX), sold 3,261 shares on March 17, 2026. The shares were disposed at $22.82 per share for gross proceeds of $74,416. This was a sale (not a purchase)—sales are often routine income- or planning-related transactions and do not necessarily indicate a change in company outlook.

Key Details

• Transaction date: March 17, 2026; Price: $22.82 per share; Shares sold: 3,261; Proceeds: $74,416.
• Report filed: March 19, 2026 (filed within the standard reporting window for Form 4).
• Reported transaction type: "Open market or private sale" (code S).
• Footnote: Sale executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Slonin on August 12, 2025. A 10b5-1 plan indicates the trades were preplanned and intended to provide safe-harbor from insider trading concerns.
• Shares owned after the transaction: Not specified in the information provided in this summary.

Context

• Because this sale was made under a 10b5-1 plan, it was pre-established and typically considered routine rather than a discretionary sale tied to recent company events.
• For retail investors, purchases by insiders tend to be more informative as potential bullish signals; single instance sales—especially under 10b5-1 plans—are common for personal liquidity or diversification and should be weighed alongside broader insider activity and company fundamentals.